The use of B-type natriuretic peptide in paediatric patients: A review of literature

Journal of Cardiovascular Medicine

Volumn 10, Issue 4, 2009, Pages 298-302

  Favilli, Silvia ^a,b   Frenos, Stefano ^a   Lasagni, Donatella ^b   Frenos, Filippo ^a   Pollini, Iva ^a   Bernini, Gabriella ^a   Aricò, Maurizio ^a   Bini, Roberta M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

B type natriuretic peptide; Cardiological marker; Children; Ventricular dysfunction

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; ANTINEOPLASTIC ANTIBIOTIC; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE LYMPHOBLASTIC LEUKEMIA; CARDIOVASCULAR RISK; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; HEART DISEASE; HEART VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HUMAN; MONITORING; NORMAL VALUE; PEDIATRICS; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; ADOLESCENT; AGE; BLOOD; CHILD; CONGENITAL HEART MALFORMATION; FEMALE; HEART FAILURE; MALE; PREDICTION AND FORECASTING; REFERENCE VALUE; RISK FACTOR; SEX DIFFERENCE;

ADOLESCENT; AGE FACTORS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; CHILD; CHRONIC DISEASE; FEMALE; HEART DEFECTS, CONGENITAL; HEART FAILURE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REFERENCE VALUES; RISK FACTORS; SEX FACTORS; VENTRICULAR DYSFUNCTION;

EID: 66149122578     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32832401d6     Document Type: Review

References (59)

1. Maeda K, Tsuramoto T, Wada A, Hisanaga Y, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular enddiastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135:825-832. (Pubitemid 28237306)
2. Berger R, Huelsman H, Strecker K, Bojik A, Moser P, Stanek B, Pacher R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105:2392-2397. (Pubitemid 34556391)
3. Lisy M, Babal P. Brain natriuretic peptide: the biological marker in the diagnosis of overt congestive heart failure and myocardial ischemia. Bratisl Lek Listy 2007; 108:170-173.
4. Nir A, Nasser N. Clinical value of NT-ProBNP and BNP in pediatric cardiology. J Card Fail 2005; 11:S76-S80.
5. Costello JM, Goodman DM, Green TP. A review of the natriuretic hormone system's diagnostic and therapeutic potential in critically ill children. Pediatr Crit Care Med 2006; 7:308-318.
6. Yoshibayashi M, Kamiya T, Saito Y, Nakao K, Nishioka K, Temma S, et al. Plasma brain natriuretic concentrations in healthy children from birth to adolescence: marked and rapid increase after birth. Eur J Endocrinol 1995; 133:207-209.
7. Mir TS, Marohn S, Laer S, Eiselt M, Grollmus O, Weil J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002; 110:e76.
8. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children and adolescents. Heart 2003; 89:875-878. (Pubitemid 36920810)
9. Nir A, Bar-Oz B, Perles Z, Brooks R, Korach A, Rein AJJT. N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart disease. Acta Paediatr 2004; 93:603-607.
10. Schwachten L, Herrmann M, Georg T, Schwarz P, Marx N, Lindinger A. Reference values of NT-pro BNP serum concentrations in the umbilical cord blood and in healthy neonates and children. Z Kardiol 2005; 94:399-404. (Pubitemid 40921968)
11. Mir TS, Flato M, Falkenberg J, Haddad M, Budden R, Weil J, et al. Plasma concentrations of N-terminal brain natriuretic peptide in healthy children, adolescents and young adults: effects of age and gender. Pediatr Cardiol 2006; 27:73-77.
12. Zhang WL, Du ZD. Mean values of brain natriuretic peptide in 190 healthy children. Zhongguo Dang Dai Er Ke Za Zhi 2006; 8:177-180.
13. Albers S, Mir TS, Haddad M, Laer S. N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. Clin Chem Lab Med 2006; 44:80-85. (Pubitemid 43010651)
14. Westerlind A, Wahlander H, Lindstedt G, Lundberg PA, Holmgren D. Clinical signs of heart failure are associated with increased levels of natriuretic peptide types B and A in children with congenital heart defects or cardiomyopathy. Acta Paediatr 2004; 93:340-345. (Pubitemid 38316556)
15. Fried I, Bar-Oz B, Perles Z, Reind AJ, Zonis Z, Nir A. N-Terminal pro-B-type natriuretic peptide levels in acute versus chronic left ventricular dysfunction. J Pediatr 2006; 149:28-31. (Pubitemid 44081925)
16. Tan LH, Jefferies JL, Liang JF, Denfield SW, Dreyer WJ, Mott AR, et al. Concentrations of brain natriuretic peptide in the plasma predicts outcomes of treatment of children with decompensated heart failure admitted to the intensive care unit. Cardiol Young 2007; 17: 397-406.
17. Price JF, Thomas AK, Grenier M, Eidem BW, O'Brian Smith E, Denfield SW, et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 2006; 114:1063-1069. (Pubitemid 44358883)
18. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, et al., Pediatric Carvedilol Study Group (2007). Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007; 298:1214-1216. (Pubitemid 47403103)
19. Koulouri S, Acherman RJ, Wong PC, Chen LS, Lewis AB. Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr Cardiol 2004; 25:341-346. (Pubitemid 38989517)
20. Cohen S, Springer C, Avital A, Perles Z, Rein AJJT, Argaman Z, Nir A. Amino-terminal pro-brain-type natriuretic peptide: heart or lung disease in pediatric respiratory distress? Pediatrics 2005; 115:1347-1350.
21. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 19:202-209. (Pubitemid 34084622)
22. Bal L, Thierry S, Brocas E, Van de Louw A, Pottecher J, Hours S, et al. B-type natriuretic peptide (BNP) and N-terminal-pro BNP for heart failure diagnosis in shock or acute respiratory distress. Acta Anaesthesiol Scand 2006; 50:340-347.
23. Bolger AP, Sharma R, Li W, Leenarts M, Kaira PR, Kemp M, et al. Neurohumoral activation and the congenital heart failure syndrome in adults with congenital heart disease. Circulation 2002; 106:92-99. (Pubitemid 34747447)
24. Mir TS, Haun C, Lilje C, Laer S, Weil J. Utility of N-terminal brain natriuretic peptide plasma concentrations in comparison to lactate and troponin in children with congenital heart disease following open-heart surgery. Pediatr Cardiol 2006; 27:209-216.
25. Cowley CG, Bradley JD, Shaddy RF. B-type natriuretic peptide levels in congenital heart disease. Pediatr Cardiol 2004; 25:336-340. (Pubitemid 38989516)
26. Holmgren D, Westerlind A, Lundberg PA, Wahlander H. Increased plasma levels of natriuretic peptide type B and A in children with congenital heart defects with left compared with right ventricular volume overload and pressure overload. Clin Physiol Funct Imaging 2005; 25:263-269. (Pubitemid 41223528)
27. Mainwaring RD, Parise C, Wright SN, Juris AL, Achtel RA, Failah H. Brain natriuretic peptide levels before and after ventricular septal defect repair. Ann Thorac Surg 2007; 84:2066-2069. (Pubitemid 350122426)
28. Ozhan H, Albayrak S, Uzun H, Ordu S, Kaya A, Yasici M. Correlation of plasma B type natriuretic peptide with shunt severity in patients with atrial or ventricular septal defect. Pediatr Cardiol 2007; 28:272-275. (Pubitemid 46976647)
29. Koch A, Kitzsteiner T, Zink S, Cesnjevar R, Singer H. Impact of cardiac surgery on plasma levels of B-type natriuretic peptide in children with congenital heart disease. Int J Cardiol 2007; 114:339-344. (Pubitemid 44855912)
30. Wu YR, Chen SB, Sun K, Huang MR, Zhang YQ, Chen S. Diagnostic value of the currently used criteria and brain natriuretic peptide for diagnosing congestive heart failure in children with congenital heart disease. Zhonghua Er Ke Za Zhi 2006; 44:728-732.
31. Berry JG, Askovich B, Shaddy RE, Hawkins JA, Cowley CG. Prognostic value of B-type natriuretic peptide in surgical palliation of children with single-ventricle congenital heart disease. Pediatr Cardiol 2008; 29:70-75.
32. Koch A, Zink S, Singer H. B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 2006; 27:861-866.
33. Law YM, Keller BB, Feingold BM, Boyle GJ. Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol 2005; 95:474-478. (Pubitemid 40247541)
34. Festa P, Ait-Ali L, Prontera C, De Marchi D, Fontana M, Emdin M, Passing C. Amino-terminal fragment of pro-brain natriuretic hormone identifies functional impairment and right ventricular overload in operated tetralogy of Fallot patients. Paediatr Cardiol 2007; 28:339-345. (Pubitemid 47415600)
35. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukaemia in childhood. N Engl J Med 1991; 324:808-815.
36. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukaemia. J Clin Oncol 2005; 23:2629-2636.
37. Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001; 37:4-9. (Pubitemid 32613628)
38. Soker M, Kervancioglu M. Plasmaconcentrations of NT-pro-BNPand cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J 2005; 26:1197-1202. (Pubitemid 41288627)
39. Erkus B, Demirtas S, Yarpuzlu AA, Can M, Genc Y, Karaka L. Early prediction of anthracycline induced cardiotoxicity. Acta Paediatr 2007; 96:506-509. (Pubitemid 46466109)
40. Ekstein S, Nir A, Rein AJ, Perles Z, Bar-Oz B, Salpeter L, et al. N-terminalproB- type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol 2007; 29:440-444. (Pubitemid 47026244)
41. Germanakis I, Kalmanti M, Parthenakis F, Nikitovic D, Stiakaki E, Patrianakos A, Vardas PE. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricular mass in children treated with anthracyclines. Int J Cardiol 2006; 108:212-215. (Pubitemid 43330616)
42. Aggarwal S, Pettersen MD, Bhambhani K, Gurczynski J, Thomas R, L'ecuyer T. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer 2007; 49:812-816.
43. Pinarly PG, Oguz A, Tunaoglu FS, Karadeniz C, Gokcora N, Elbeg S. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer 2005; 44:370-377. (Pubitemid 40316030)
44. Jackowska T, Wasilewski R. Usefulness of determining the blood levels of B-type natriuretic peptide in the evaluation of cardiotoxicity in children treated with anthracyclines. Med Wieku Rozwoj 2006; 10:767-774.
45. Bryant J, Picot J, Baxter L, Levitt G, Sullivan I, Clegg A. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur J Cancer 2007; 43:1959-1966. (Pubitemid 47299200)
46. Kaditis A, Alexopulos EI, Hatzi F. Overnight change in brain natriuretic peptide levels in children with sleep-disordered breathing. Chest 2006; 130:1377-1384. (Pubitemid 44786729)
47. Khan K, Talwar S. Screening for familial hypertrophic cardiomyopathy using brain natriuretic peptide [letter]. Eur Heart J 1999; 20:550. (Pubitemid 29149955)
48. Oana S, Terai M, Tanabe M, Hohno Y, Ohnuma N. Plasma brain natriuretic peptides and renal hypertension. Pediatr Nephrol 2000; 14:813-815. (Pubitemid 30462174)
49. Kawamura T, Wago M, Kawagushi H, Tahara M, Yuge M. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 2000; 42:241-248. (Pubitemid 30409336)
50. Kurotobi S, Kawakami N, Shimizu K, Nasuno S, Takahashi K, Togaki S, Ozono K. Brain natriuretic peptide as a hormonal marker of ventricular diastolic dysfunction in children with Kawasaki disease. Pediatr Cardiol 2005; 26:425-430. (Pubitemid 43004590)
51. Takeuchi D, Tsutomu S, Takatsuki S, Fujiwara M. Abnormal tissue Doppler images are associated with elevated plasma brain natriuretic peptide and increased oxidative stress in acute Kawasaki disease. Circ J 2007; 71:357-362. (Pubitemid 46414823)
52. Fried I, Bar-Oz B, Algur N, Fried E, Gavri S, Yatsiv I, et al. Comparison of N-terminal pro-β-type natriuretic peptide levels in critically ill children with sepsis versus acute left ventricular dysfunction. Pediatrics 2006; 118:e1165-e1168.
53. Hoffmann M, Brueckmann M, Bertsch T, Wiessner M, Liebetrau C, Lang S, et al. Increased plasma levels of NT-proANP and NT-proBNP as markers of cardiac dysfunction in septic patients. Clin Lab 2005; 51:373-379. (Pubitemid 41179670)
54. Van Albada ME, Loot FG, Fokkama R, Roofthooft MT, Berger RM. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res 2008; 63:321-327. (Pubitemid 351301465)
55. Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol 2008 Jul 1. [Epub ahead of print].
56. Reynolds EW, Ellington JG, Vranicar M, Bada HS. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 2004; 114:1297-1304. (Pubitemid 41647692)
57. Sanjeev S, Pettersen M, Lua J, Thomas R, Shankaran S, L'Ecuyer T. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol 2005; 25:709-713. (Pubitemid 41655645)
58. Choi BM, Lee KH, Eun BL, Yoo KH, Hong YS, Son CS, Lee JW. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005; 115:255-261.
59. Rossano JW, Denfield SW, Kim JJ, Price JF, Jefferies JL, Decker JA, et al. B-type natriuretic peptide is a sensitive screening test for acute rejection in pediatric heart transplant patients. J Heart Lung Transplant 2008; 27:649-654.